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ABSTRACT
The recent description of chronic hepatitis E in
organ transplant recipients deserves increased
awareness in the context of hepatitis E virus
(HEV) infection in immunocompromised individ-
uals. Reported here is what is apparently the ﬁrst
PCR-documented case of acute hepatitis E in a
human immunodeﬁciency virus (HIV)-1-infected
patient. The CD4+ T-lymphocyte count was
246 ⁄mm3. The IgM anti-HEV antibody and HEV
RNA tests results from serum were positive.
Hepatitis was benign, and chronic HEV infection
was ruled out. The HEV genotype was 3f. The
patient did not report recent travel abroad. HEV
should be tested in HIV-infected individuals
presenting with acute hepatitis. HEV RNA detec-
tion is useful in diagnosing HEV infection and in
monitoring recovery.
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Hepatitis E virus (HEV) is the leading, or the
second leading, cause of acute hepatitis in adults
in many parts of the developing world, where it is
principally waterborne. However, seroprevalence
data suggest that HEV might be endemic in
industrialized countries as well [1]. Moreover, an
increasing number of sporadic autochthonous
cases of hepatitis E have been recently reported
in these geographical areas, and some of them
were fatal [1,2]. Although HEV epidemiology
remains poorly understood in developed coun-
tries, there is increasing evidence that hepatitis E
is a zoonosis with a swine reservoir, which might
be a source of contamination for humans [1].
Recently, very unexpected clinical features of
hepatitis E have been highlighted in immunosup-
pressed individuals. Indeed, chronic hepatitis E,
and even rapidly progressing hepatitis E-associ-
ated cirrhosis, have been described in organ trans-
plant recipients [3–5]. Hence, these data deserve
increased attention in the context of hepatitis E in
immunocompromised individuals. Reported here
is apparently the ﬁrst PCR-documented case of
acute HEV infection in a patient infected with the
human immunodeﬁciency virus (HIV).
A 49-year-old male with sexually-acquired
HIV-1 infection presented in September 2007 with
fever, asthaenia and hepatomegaly. The alanine
aminotransferase (ALT) level was 813 IU ⁄L, bili-
rubinaemia was 31 lmol ⁄L, and the prothrombin
index was 100% (Table 1). The CD4+
T-lymphocyte count was 246 ⁄mm3, and the
plasma HIV-1 RNA level was 2.9 log10 copies ⁄mL
under treatment with tenofovir, abacavir, ataz-
anavir and ritonavir. The patient reported chronic
excessive alcohol consumption, and he reported
having multiple sexual partners. Hepatitis E was
diagnosed on the basis of positive results after
IgM anti-HEV antibody testing (EIAGen kit,
Adaltis; optical density ratios for IgG and IgM
anti-HEV antibodies were 0.79 and 10.1, respec-
tively) and HEV RNA detection and sequencing
from serum [6]. Other aetiologies for acute hep-
atitis were excluded, including hepatitis A virus,
hepatitis B virus and hepatitis C virus infection.
Neither HEV RNA nor anti-HEV antibodies were
detected 2 months prior to the onset of hepatitis.
Clinical symptoms spontaneously regressed dur-
ing the following month, and in January 2008 the
ALT level was 10 IU ⁄L. At that time, IgG anti-
HEV antibody seroconversion had occurred, IgM
anti-HEV antibodies still persisted, and HEV
RNA was no longer detected in serum.
The patient did not report recent travel abroad,
contacts with travellers, or consumption of wild
boar meat or shellﬁsh. Nevertheless, he reported
eating barbecued pork 2 weeks before onset of
hepatitis. The HEV RNA ORF-2 sequence clus-
tered into genotype 3f, which is found in cases of
autochthonous hepatitis E and in swine in Europe
Table 1. Evolution of biochemical, haematological and virological markers
Marker
Date
6 June 2007 18 June 2007 6 July 2007 17 September 2007 22 January 2008
Alanine aminotransferase (IU ⁄L) 29 15 10 813 10
Aspartate aminotransferase (IU ⁄L) 22 19 17 714 22
c- Glutamyl transferase (IU ⁄L) 73 43 34 778 26
Bilirubinaemia (lmol ⁄L) 11 6 11 31 60
Alkaline phosphatase (IU ⁄L) 90 82 51 204 71
Prothrombin index (%) 100 100 100 100 –
Platelet count (per mm3) 181 304 258 212 –
Lymphocyte T-CD4 cell count (per mm3) 462 248 231 246 –
HEV RNA in seruma Negative – – Positive Negative
Anti-HEV IgG antibodiesa Negative – Negative Negative Positive
Optical density ratiob <0.9 – <0.9 <0.9 3.6
Anti-HEV IgM antibodiesa Negative – Negative Positive Positive
Optical density ratiob <0.9 – <0.9 10.0 7.7
HBV serology – – – Negative –
HBV DNA in serum (IU ⁄mL) – – – Negative –
Anti-HCV antibodies – – – Negative –
HCV RNA in serum (IU ⁄mL) – – – Negative –
HIV-1 RNA in serum (copies ⁄mL) <40 87 366 489 543 829 <40
Antiretroviral therapy Interruption of
treatment that included
ABC, TDF, fosAPV, and RTVc
None Re-introduction of
treatment that included
ABC, TDF, ATV, and RTV
ABC, TDF, ATV, RTV ABC, TDF, ATV, RTV
), Not available; HEV, hepatitis E virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeﬁciency virus; ABC, abacavir; TDF, tenofovir; fosAPV,
fosamprenavir; RTV, ritonavir; ATV, atazanavir.
aRetrospective analysis of serum samples could be performed due to their availability for routine laboratory examinations in the context of HIV infection.
bPositivity corresponds to an optical density ratio >1.
cInterruption of antiviral therapy was motivated by severe lipodystrophia.
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[7,8] (Fig. 1). Thus, the HEV sequences corre-
sponding to the ten BLAST hits with the highest
scores with respect to the sequence from the case
reported here were from French and Spanish
humans or swine (http://www.ncbi.nlm.nih.
gov/BLAST/).
Hepatitis E might represent an important clin-
ical problem in HIV-seropositive individuals.
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Fig. 1. Phylogenetic tree based on partial nucleotide sequence of the open reading frame 2 (ORF2) region of the hepatitis E
virus (HEV) genome obtained from the patient whose case is reported herein together with HEV sequences: (i) from human
cases diagnosed in the Timone Virology laboratory of Marseille; (ii) of previously determined genotypes and subtypes [7];
and (iii) from GenBank and corresponding to the ten highest-score BLAST hits with the sequence from the present case
(http://www.ncbi.nlm.nih.gov/BLAST/). The phylogenetic tree was constructed by the neighbour-joining method based
on the partial nucleotide sequences of the 5¢-ORF2 region of HEV genome (230 bp). The HEV sequence from the case
reported here is in bold and is indicated by a black square. HEV sequences from human cases diagnosed in the Timone
Virology laboratory of Marseille are indicated by black circles. The HEV sequences corresponding to the ten BLAST hits
obtained with the sequences from the case reported here are indicated by white triangles. They are labelled as follows:
GenBank accession no., source and country of origin. Bootstrap values are indicated when they were >60% (percentage
obtained from 1000 resamplings of the data). Avian HEV sequence GenBank accession no. AY043166 was used as an
outgroup. The scale bar indicates the number of nucleotide substitutions per site. BBH, best BLAST hits; Av, Avian; Hu,
Human; Sew, Sewage; Sw, Swine; Fr, France; Mars, Marseille (France); Sp, Spain.
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First, recent reports from India and Europe
indicate that hepatitis E could aggravate prior
chronic viral hepatitis and that it carries a poor
prognosis in the context of chronic liver disease
[2,9,10]. This might be critical in HIV-infected
patients with high rates of chronic co-infections
with hepatitis B virus and ⁄ or hepatitis C virus,
especially those with a history of injecting drug
use [11]. Second, it has been very recently sug-
gested that HEV infection might result in chronic
hepatitis, and even cirrhosis in the setting of
severe immunosuppression, in organ transplant
recipients [3–5].
To date, the clinical presentation and outcome
of hepatitis E in HIV-seropositive individuals are
unknown. Indeed, the association between HEV
and HIV infections has been debated mostly on
the basis of IgG anti-HEV antibody seropreva-
lence data from developed countries, and this
debate revealed controversial results [12–17]. In
these studies, acute hepatitis E was not described.
Moreover, discordance between the results of IgG
anti-HEV antibody detection assays has been
previously reported, and this discordance com-
plicates the interpretation of HEV seroprevalence
studies [18]. In another seroprevalence study from
Malaysia, IgM anti-HEV antibodies were found in
4% of HIV-1-infected patients, in the absence of
IgG anti-HEV antibodies in all cases [19]. How-
ever, their clinical signiﬁcance was difﬁcult to
assess, as no individual complained of symptoms
of acute hepatitis. Very recently, hepatitis E was
reported in an HIV-positive pregnant Nigerian
woman living in Germany, whose CD4+ T-lym-
phocyte count was >200 ⁄mm3 [20]. HEV infection
was diagnosed at week 27 of pregnancy only on
the basis of positive results according to IgG anti-
HEV antibody testing, with HEV RNA not being
tested. The ALT level was 1683 IU ⁄L, and the
beginning of liver failure was noted. Neverthe-
less, the clinical outcome was favourable.
In the case described here, hepatitis E
was benign, and the clinical outcome was also
favourable. These outcomes may have been due
to the absence of underlying chronic hepatitis B
and C [20]. In addition, in the present case,
the PI before acute hepatitis was 100%.
Furthermore, chronic HEV infection was ruled
out, as assessed by longitudinal HEV RNA
testing. The resolution of HEV infection may
be explained by the patient’s moderate level of
immunosuppression, as indicated by a CD4+
T-lymphocyte count >200 ⁄mm3. Indeed, in the
study by Kamar et al. [4], total lymphocyte
and CD4+ T-cell counts were signiﬁcantly lower
in organ transplant recipients in whom chronic
hepatitis E developed than in those in whom
hepatitis E resolved.
Finally, in the case described here, and in
contrast to the case reported by Thoden et al. [20],
hepatitis E was diagnosed on the basis of positive
results according to IgM anti-HEV antibody and
HEV RNA testing, whereas IgG anti-HEV anti-
bodies were detected only 4 months after hepati-
tis onset. In the study by Kamar et al. [4], IgG
anti-HEV antibodies were detected in only one of
14 organ transplant recipients at the time of
diagnosis of hepatitis E. Furthermore, persistently
negative results of IgG anti-HEV antibody testing
have previously been observed in PCR-docu-
mented HEV infections in immunosuppressed
individuals [3–5, 21]. These data make apparent
the need for systematic testing for HEV RNA and
IgM anti-HEV antibodies in such patients, to
diagnose HEV infection.
In conclusion, HEV testing should be included
in diagnostic investigations of acute hepatitis in
HIV-infected individuals. HEV RNA should be
assayed for reliable diagnosis of hepatitis E, and
its negativation should be monitored to verify the
complete recovery from HEV disease.
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Panton–Valentine leukocidin is expressed
at toxic levels in human skin abscesses
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ABSTRACT
Pus samples were prospectively collected from
patients with Staphylococcus aureus skin infections
and tested for Panton–Valentine leukocidin
(PVL). PVL was detected at concentrations that
were toxic for rabbit skin in all specimens from
patients infected with strains harbouring PVL
genes.
Keywords ELISA, Panton–Valentine leukocidin, quan-
tiﬁcation, skin infection, Staphylococcus aureus
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Staphylococcus aureus is an important human
pathogen that expresses a variety of exoproteins,
including Panton–Valentine leukocidin (PVL) [1].
PVL genes are carried by community-acquired
methicillin-resistant S. aureus (CA-MRSA) clones
that are spreading throughout the world [2,3].
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